Cour Pharmaceuticals Development Co., Inc.

Cour Pharmaceuticals Development Co., Inc. is a biotechnology and pharmaceutical company founded in 2015, headquartered in the United States. The company's slogan "First-in-class therapies designed to reprogram the immune system" reflects its dedication to finding treatments and cures for a variety of diseases. Cour Pharmaceuticals utilizes novel nanoparticle-based technologies to attack diseases directly, aiming to provide treatments and cures previously unavailable to doctors and their patients. The company recently received a significant Series A investment of $105.00M on 30 January 2024. The investors in this round included prominent names such as T1D Fund, Angelini Ventures, Lumira Ventures, Roche Venture Fund, Bristol-Myers Squibb, Pfizer Breakthrough Growth Initiative, and Alpha Wave Ventures. Cour Pharmaceuticals' strategic approach, combined with its strong network of medical and scientific partners, positions the company as a promising player in the biotech and pharmaceutical industries. With its innovative therapies and impressive investor backing, the company is well-positioned for future growth and to make a significant impact in the healthcare sector.